Stock analysis, AI verdict, fundamentals & technical signals
Rating: BUY
Price: $80.46 Analyst target: $141.00 Upside: 75.24%
Corcept Therapeutics Incorporated discovers, develops, and markets drugs for the treatment of severe metabolic, cancer, and psychiatric disorders in the United States. The company is headquartered in Menlo Park, California.
See the full interactive analysis & chart →Informational only — not investment advice.